On Jun 29, 2018 Viking Therapeutics (NASDAQ:VKTX) with $15 Target Was Coveraged By Raymond James.

June 29, 2018 - By Matthew Medley

Viking Therapeutics, Inc. (NASDAQ:VKTX) Corporate Logo

What Price Target Has Raymond James Given Viking Therapeutics (NASDAQ:VKTX)

Today a note was released, in which Raymond James analyst initiated coverage of Viking Therapeutics (NASDAQ:VKTX) with Outperform rating. The Investment analysts give $15 target price which suggests upside potential of 57.40 % on VKTX’s shares.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Coverage

In total 5 analysts cover Viking Therapeutics (NASDAQ:VKTX). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:VKTX)’s analyst reports since March 8, 2018 according to StockzIntelligence Inc. In Friday, June 1 report H.C. Wainwright maintained it with “Buy” rating and $1500 target. On Thursday, March 8 the stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) earned “Buy” rating by Roth Capital. On Friday, June 1 the firm has “Buy” rating given by Maxim Group. On Monday, March 26 the stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) has “Buy” rating given by H.C. Wainwright.

The stock decreased 2.51% or $0.2457 during the last trading session, reaching $9.5343.Viking Therapeutics, Inc. has volume of 1.31 million shares. Since June 29, 2017 VKTX has risen 320.16% and is uptrending. VKTX outperformed the S&P 500 by 307.59%.

On August, 8 Viking Therapeutics, Inc. (NASDAQ:VKTX)’s earnings release is anticipated by WallStreet, RTT reports. Analysts predict $-0.12 EPS, which is $0.09 up or 42.86 % from 2017’s $-0.21 EPS. Wall Street predicts 20.00 % negative EPS growth as of August, 8.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.The company has $567.85 million market cap. The Company’s lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.Last it reported negative earnings. The firm is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia.

For more Viking Therapeutics, Inc. (NASDAQ:VKTX) news posted briefly go to: Seekingalpha.com, Fool.com, Fool.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Viking Therapeutics: What Now After ‘Yuge’ Rally?” posted on June 12, 2018, “Why Viking Therapeutics Stock Is On Fire Today” on May 31, 2018, “3 Growth Stocks at Deep-Value Prices” with a publish date: June 15, 2018, “Viking Therapeutics: Hallmark Moment” and the last “Viking Therapeutics: Sell The Pop On The Sympathy Play” with publication date: June 01, 2018.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.